Loading organizations...
§ Private Profile · Eindhoven, Netherlands
Onera Health is a technology company.
Onera Health develops the Onera Sleep Test System (STS), a patch-based polysomnography (PSG) solution for in-lab and home diagnostics. This no-wire, user-friendly system captures essential physiological signals, delivering gold-standard clinical-grade PSG. Its core technology offers a less intrusive method for comprehensive sleep assessment.
Onera Health was founded in 2017 in the Netherlands by Ruben de Francisco and Iulia Dobai. De Francisco, leveraging his leadership in wearable healthcare at IMEC, identified significant inconveniences in conventional sleep study methods. This insight drove the creation of a more accessible, comfortable diagnostic approach for prevalent sleep disorders.
The company’s offerings serve clinicians seeking accurate, efficient diagnostics, and patients benefiting from a comfortable testing experience. Onera’s "PSG-as-a-service" model integrates proprietary hardware with its cloud-based Digital Health Platform for end-to-end sleep diagnostics. Onera Health aims to transform sleep medicine by making high-quality diagnostics widely available.
Onera Health has raised $54.8M across 3 funding rounds.
Onera Health has raised $54.8M in total across 3 funding rounds.
Onera Health has raised $54.8M in total across 3 funding rounds.
Onera Health's investors include Michaël Vlemmix, Drew Burdon, Atlantic Bridge, EQT Life Sciences, 15th Rock, BOM, imec.xpand, Innovation Industries, Harm de Vries, Tom Vanhoutte, Jazz Pharmaceuticals, imec.
Onera Health has raised $54.8M across 3 funding rounds. Most recently, it raised $33.0M Series C in January 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 1, 2024 | $33M Series C | Michaël Vlemmix, Drew Burdon | Atlantic Bridge, EQT Life Sciences, 15th Rock, BOM, Imec.xpand, Innovation Industries | Announced |
| Jul 29, 2021 | $12.4M Series B | Harm DE Vries | 15th Rock, BOM, TOM Vanhoutte, Jazz Pharmaceuticals | Announced |
| Apr 24, 2019 | $9.3M Series A | — | BOM, Imec, Imec.xpand, JED Black | Announced |
Onera Health is a MedTech company developing the Onera Sleep Test System (STS), a clinical-grade, patch-based polysomnography (PSG) solution that enables wireless, at-home sleep diagnostics.[1][2][7] It serves clinicians, sleep labs, and patients by capturing key physiological signals like EEG, ECG, respiratory effort, oxygen levels, and more, solving the problem of cumbersome, hospital-bound sleep testing that limits access and increases costs.[1][4][7] The PSG-as-a-Service model combines hardware with a cloud platform for easy setup, data analysis, and reporting, with CE mark and FDA 510(k) clearance, driving growth through expansions like Japan in 2025.[2][4]
Founded in 2017 as a spin-off from imec, a leading nanoelectronics research center, Onera Health emerged from innovations in biomedical sensors and digital health technologies in Eindhoven, Netherlands.[3][9] Ruben de Francisco, the Founder and CEO, led the development of miniaturized, low-power chips for wearable diagnostics, starting with sleep monitoring.[3] Early traction came from the Onera STS, which simplified PSG from wired lab setups to self-applied patches, gaining regulatory approvals and investor backing from firms like Innovation Industries and Gimv.[2][5]
Onera rides the wave of remote diagnostics and wearable MedTech, addressing a global sleep disorder crisis affecting millions, with high prevalence in aging populations like Japan.[2][4] Timing aligns with post-pandemic demand for home-based care, easing hospital pressures amid clinician shortages and rising chronic conditions.[4] Market forces favor it: regulatory clearances boost adoption, while Brabant region's ecosystem—High Tech Campus Eindhoven, TU/e—fuels medtech innovation alongside peers like MedEye.[4][9] Onera influences the ecosystem by democratizing PSG, optimizing patient care, and expanding sensor tech to wellness and fitness.[3][6]
Onera is poised for scaled global adoption, building on Japan entry and chip tech for multi-disease monitoring in sleep, neuro, and cardiac fields.[3][4] Trends like AI-driven analysis, telehealth integration, and miniaturized wearables will accelerate growth, potentially capturing share in a $10B+ sleep diagnostics market. Its influence may evolve from sleep specialist to platform provider, partnering with health systems for anytime-anywhere PSG, ultimately transforming access for underserved patients worldwide—echoing its mission to bring hospital-grade care home.[2][7]